Participants
obesity, postprandial blood glucose, PCOS, liver and kidney function, overweight, ASRM-ESHRE, diabetes
OBESITY, THYROID DISORDERS, OBESE, HYPERPROLACTINEMIA, HYPERTRIGLYCERIDEMIA, DIABETES
This was a randomized, prospective, open-label,12-week pilot study recruiting 60 PCOS patients with obesity according to ASRM-ESHRE Rotterdam criteria and was performed exclusively at a single center (Hospital of Chengdu University of Traditional Chinese Medicine, PR China)from August 2018 to December 2019 (Eligible subjects refer to overweight and obese women(BMI≥24kg/mOur medical staff addressed 82 subjects to find and enroll potential research participants, and 75 of them voluntarily provided written informed consent. At the initial examination, participants were screened with liver and kidney function biochemical tests, blood lipid profile, fasting blood glucose, 2h postprandial blood glucose, thyroid stimulating hormone, prolactin, testosterone, and qualitative β human chorionic gonadotropin (β-hCG) to exclude increased liver enzymes and impaired kidney function, severe hypertriglyceridemia, diabetes, thyroid disorders, hyperprolactinemia, and/or pregnancy. And they were also questioned about the regularity and length of their menstrual cycle for the last 6 months. Based on their test findings, eleven individuals were determined to be ineligible.64 non-diabetic women who satisfied the requirements for obesity and PCOS were finally recruited.